| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
ERRα
DS20362725 is a targeted agonist of the Estrogen-Related Receptor alpha (ERRalpha). It functions as a chemical probe to activate ERRalpha, distinguishing it from antagonists in the same class. By binding to ERRalpha, it promotes the recruitment of coactivators and repels corepressors to stimulate gene transcription. |
|---|---|
| ln Vitro |
DS20362725 (compound 3d; 0.002, 0.006, 0.017, 0.051, 0.015, 0.046, 1.4, 4.2, 12.5 μg/mL; 18 h) stimulates the transcriptional activity of full-length ERRα in MG63 cells with an EC50 of 1.1 μM[1].
In a cell-free binding assay, DS20362725 inhibits the interaction between the RIP140 corepressor peptide and the GST-ERRalpha ligand-binding domain (LBD) with an IC50 value of 0.6 microM, indicating its strong binding affinity to the receptor.In cells, it activates ERRalpha transcriptional activity with an EC50 of 1.1 microM in a reporter assay using MG63 cells. |
| ln Vivo |
In vivo data are currently limited for this compound, as it is primarily a research tool for in vitro studies. However, due to its agonist activity, it is being explored for its potential to regulate metabolic pathways, suggesting possible future applications in animal models of diabetes and metabolic syndrome.
|
| Enzyme Assay |
Cell-free assays are performed using a fluorescence polarization (FP) competition format. The assay uses a GST-fused ERRalpha ligand-binding domain (LBD) and a fluorescein-labeled RIP140 corepressor peptide. The test compound is added to displace the peptide, and the decrease in FP signal is measured to calculate the half-maximal inhibitory concentration (IC50).
|
| Cell Assay |
Cellular transcriptional assays are performed in MG63 cells that have been transiently transfected with a full-length ERRalpha expression plasmid and a luciferase reporter gene containing an ERRalpha response element. The cells are then treated with DS20362725 for 18 hours, and the half-maximal effective concentration (EC50) for the activation of transcription is measured.
|
| Animal Protocol |
In vivo animal model data is not available for this research compound. As a chemical probe for cell-based studies, it is not typically formulated for animal pharmacokinetic or efficacy studies in a standard research setting.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties are not documented. As a laboratory chemical primarily for in vitro use, ADME (Absorption, Distribution, Metabolism, Excretion) data are not typically required or reported. Its optimization and development are focused on enhancing its potency as a chemical probe.
|
| Toxicity/Toxicokinetics |
Toxicological and safety profiles have not been formally established. This compound is intended for research use only and is not for human consumption. Standard safety precautions for handling bioactive small molecules and fine chemicals should be followed.
|
| References | |
| Additional Infomation |
DS20362725 is a selective ERRalpha agonist that serves as a valuable tool for exploring the biological function of ERRalpha and its potential as a therapeutic target for metabolic diseases such as type 2 diabetes mellitus (T2DM).
|
| Molecular Formula |
C19H22N2O2
|
|---|---|
| Molecular Weight |
310.39
|
| Exact Mass |
310.168
|
| CAS # |
2735803-20-8
|
| PubChem CID |
162641550
|
| Appearance |
Off-white to pink solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(O)=CC=C(OC2C=C3N(C)C(C)=NC3=CC=2)C=C1C(C)(C)C
|
| InChi Key |
LQWRSCHPPDJXLC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H22N2O2/c1-12-20-16-8-6-14(11-17(16)21(12)5)23-13-7-9-18(22)15(10-13)19(2,3)4/h6-11,22H,1-5H3
|
| Chemical Name |
2-tert-butyl-4-(2,3-dimethylbenzimidazol-5-yl)oxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 10 mg/mL (32.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2218 mL | 16.1088 mL | 32.2175 mL | |
| 5 mM | 0.6444 mL | 3.2218 mL | 6.4435 mL | |
| 10 mM | 0.3222 mL | 1.6109 mL | 3.2218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
